These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 18518891

  • 1. Combination statin-fibrate therapy: safety aspects.
    Franssen R, Vergeer M, Stroes ES, Kastelein JJ.
    Diabetes Obes Metab; 2009 Feb; 11(2):89-94. PubMed ID: 18518891
    [Abstract] [Full Text] [Related]

  • 2. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
    Davidson MH.
    Expert Opin Drug Saf; 2006 Jan; 5(1):145-56. PubMed ID: 16370963
    [Abstract] [Full Text] [Related]

  • 3. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH.
    Am J Cardiol; 2008 Dec 22; 102(12A):41L-47L. PubMed ID: 19084089
    [Abstract] [Full Text] [Related]

  • 4. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S.
    Clin Ther; 2008 Feb 22; 30(2):294-306. PubMed ID: 18343268
    [Abstract] [Full Text] [Related]

  • 5. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
    Steinmetz A.
    Diabetes Metab Res Rev; 2008 Feb 22; 24(4):286-93. PubMed ID: 18273835
    [Abstract] [Full Text] [Related]

  • 6. FIELDS of dreams, fields of tears: a perspective on the fibrate trials.
    Wierzbicki AS.
    Int J Clin Pract; 2006 Apr 22; 60(4):442-9. PubMed ID: 16620358
    [Abstract] [Full Text] [Related]

  • 7. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.
    Jones PH, Davidson MH.
    Am J Cardiol; 2005 Jan 01; 95(1):120-2. PubMed ID: 15619408
    [Abstract] [Full Text] [Related]

  • 8. Interpreting clinical trials of diabetic dyslipidaemia: new insights.
    Wierzbicki AS.
    Diabetes Obes Metab; 2009 Mar 01; 11(3):261-70. PubMed ID: 17645560
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
    Steiner G.
    Am J Cardiol; 2008 Dec 22; 102(12A):28L-33L. PubMed ID: 19084087
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
    Davidson M.
    Am J Cardiol; 2008 Dec 22; 102(12A):19L-27L. PubMed ID: 19084086
    [Abstract] [Full Text] [Related]

  • 13. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
    Ginsberg HN, Bonds DE, Lovato LC, Crouse JR, Elam MB, Linz PE, O'connor PJ, Leiter LA, Weiss D, Lipkin E, Fleg JL, ACCORD Study Group.
    Am J Cardiol; 2007 Jun 18; 99(12A):56i-67i. PubMed ID: 17599426
    [Abstract] [Full Text] [Related]

  • 14. Clinical insights from the Fenofibrate Intervention and Event Lowering in Diabetes study: a community practice perspective.
    Toth PP.
    Int J Clin Pract; 2009 Jun 18; 63(6):903-11. PubMed ID: 19490201
    [Abstract] [Full Text] [Related]

  • 15. The role of fenofibrate in clinical practice.
    Zambon A, Cusi K.
    Diab Vasc Dis Res; 2007 Sep 18; 4 Suppl 3():S15-20. PubMed ID: 17935056
    [Abstract] [Full Text] [Related]

  • 16. Combination therapy for the treatment of dyslipidemia.
    Streja D.
    Curr Opin Investig Drugs; 2004 Mar 18; 5(3):306-12. PubMed ID: 15083597
    [Abstract] [Full Text] [Related]

  • 17. Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus.
    Reyes-Soffer G, Rondon-Clavo C, Ginsberg HN.
    Expert Opin Pharmacother; 2011 Jun 18; 12(9):1429-38. PubMed ID: 21426238
    [Abstract] [Full Text] [Related]

  • 18. Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD.
    Vergès B.
    Curr Opin Lipidol; 2006 Dec 18; 17(6):653-8. PubMed ID: 17095910
    [Abstract] [Full Text] [Related]

  • 19. Fenofibrate and cardiovascular risk: a synopsis and commentary on (FIELD).
    Bailey CJ.
    Diabet Med; 2006 Feb 18; 23(2):109-12. PubMed ID: 16433706
    [No Abstract] [Full Text] [Related]

  • 20. Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensity-score and instrumental variable methods to adjust for treatment-selection bias.
    Suh HS, Hay JW, Johnson KA, Doctor JN.
    Pharmacoepidemiol Drug Saf; 2012 May 18; 21(5):470-84. PubMed ID: 22461130
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.